Low dose radiotherapy in indolent lymphomas, enough is enough

Hematological Oncology

Volumn 27, Issue 2, 2009, Pages 71-81

  Haas, R L M ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Indolent lymphoma; Radiotherapy

Indexed keywords

CD68 ANTIGEN; CYCLOPHOSPHAMIDE; DEATH RECEPTOR 5; LIPOCORTIN 5; PREDNISONE; PROTEIN P53; TECHNETIUM 99M; VINCRISTINE;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CELL CYCLE ARREST; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DENDRITIC CELL; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; FOLLICULAR LYMPHOMA; GENE EXPRESSION PROFILING; GENE TARGETING; HUMAN; INNATE IMMUNITY; LARGE CELL LYMPHOMA; LOW DOSE INVOLVED FIELD RADIOTHERAPY; LOW ENERGY RADIATION; LYMPHOMA; MACROPHAGE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION FIELD; RADIATION RESPONSE; REVIEW; WHOLE BODY RADIATION;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LYMPHATIC IRRADIATION; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASM PROTEINS; NEOPLASM STAGING; PALLIATIVE CARE; RADIATION TOLERANCE; RADIOTHERAPY DOSAGE; TUMOR SUPPRESSOR PROTEIN P53; WHOLE-BODY IRRADIATION;

EID: 66949131474     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.882     Document Type: Review

References (75)

1. Cartwright R, Brincker H, Carli PM, et al. The rise in incidence of lymphomas in Europe 1985-1992. Eur J Cancer 1999; 35: 627-633.
2. Vose JM, Chiu BC, Cheson BD, Dancey J, Wright J. Update on epidemiology and therapeutics for non-Hodgkin's lymphoma. Hematology 2002; 1: 241-262.
3. Reiser M, Diehl V. Current treatment of follicular non-Hodgkin's lymphoma. Eur J Cancer 2002; 38: 1167-1172.
4. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993; 20: 75-88.
5. Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005; 23: 8447-8452.
6. Portlock CS, Rosenberg SA, Glatstein E. Management of low-grade non-Hodgkin's lymphomas. Sem Oncol 1990; 17: 51-59.
7. Lister TA. The management of follicular lymphoma. Ann Oncol 1991; 2: 131-135.
8. Rohatiner AZS, Lister TA. New approaches to the treatment of follicular lymphoma. Br J Haematol 1991; 79: 349-354.
9. Horning SJ. Treatment approaches to the low-grade lymphomas. Blood 1994; 83: 881-884.
10. Kimby E, Bjorkholm M, Gahrton G, et al. Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol 1994; 5 (Suppl 2): 67-71.
11. Mendenhall NP, Lynch W. The low-grade lymphomas. Semin Radiat Oncol 1995; 5: 254-266.
12. Chau I, Jones R, Cunningham D, et al. Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy? Br J Cancer 2003; 89: 36-42.
13. Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 2004; 22: 1454-1459.
14. Ardeshna KM, Smith P, Norton A, et al. British national lymphoma investigation. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003; 362: 516-522.
15. Shipp MA, Harrington DP. A predictive model for aggressive non-Hodgkin's lymphoma. The international non-Hodgkin's lymphoma prognostic factors project. N. Engl J Med. 1993; 329: 987-994.
16. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258-1265.
17. Paryani SB, Hoppe RT, Cox RS, Colby TV, Rosenberg SA, Kaplan HS. Analysis of non-Hodgkin's lymphomas with nodular and favorable histologies, stages I and II. Cancer 1983; 52: 2300-2307.
18. Lawrence TS, Urba WJ, Steinberg SM, Sundeen JT, Cossman J, Young RC. Retrospective analysis of stage I and II indolent lymphomas at the National Cancer Institute. Int J Radiat Oncol Biol Phys 1988; 14: 417-424.
19. MacManus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? J Clin Oncol 1996; 14: 1282-1290.
20. Frank C, Zierhut D, Schulz-Ertner D, Wannenmacher M. Centroblastic centrocytic non-Hodgkin's lymphoma stage I-III: patterns of failure following radiotherapy. Strahlenther Onkol 2001; 177: 597-603.
21. Denham JW, Denham E, Dear KB, Hudson GV. The follicular non-Hodgkin's lymphomas-I. The possibility of cure. Eur J Cancer 1996; 3: 470-479.
22. Sutcliffe SB, Gospodarowicz MK, Bush RS, et al. Role of radiation therapy in localized non-Hodgkin's lymphoma. Radiother Oncol 1985; 4: 211-223.
23. Vaughan Hudson B, Vaughan Hudson G, MacLennan KA, Anderson L, Linch DC. Clinical stage I non-Hodgkin's lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy as initial treatment. Br J Cancer 1994; 69: 1088-1093.
24. Spry NA, Lamb DS, Vaughan Hudson G, Easterling MJ, MacLennan KA, Jelliffe AM. Localized grade I non-Hodgkin's lymphoma: results of treatment with radiotherapy alone in 88 patients. Clin Oncol 1989; 1: 33-38.
25. Richaud PM, Soubeyran P, Eghbali H, et al. Place of low-dose total body irradiation in the treatment of localized follicular non-Hodgkin's lymphoma: results of a pilot study. Int J Radiat Oncol Biol Phys 1998; 40: 387-390.
26. Finke J. The role of stem cell transplantation in the treatment of follicular lymphoma. Semin Cancer Biol. 2003; 13: 233-239.
27. Mauch P. Follicular non-Hodgkin's lymphoma: the role of radiation therapy. Ann Hematol 2001; 80: 63-65.
28. McLaughlin P, Fuller LM, Velasquez WS, Sullivan-Halley JA, Butler JJ, Cabanillas F. Stage I-II follicular lymphoma. Treatment results for 76 patients. Cancer 1986; 58: 1596-1602.
29. Girinsky T, Guillot-Vals D, Koscielny S, et al. A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment. Int J Radiat Oncol Biol Phys 2001; 51: 148-155.
30. Johnson RE. Management of generalized malignant lymphoma with 'systemic' radiotherapy. Br J Cancer 1975; 31: 450-455.
31. Chaffey JT, Rosenthal DS, Pinkus F, Hellman S. Advanced lymphosarcoma treated by total body irradiation. Br J Cancer 1975; 31: 441-449.
32. Chaffey JT, Rosenthal DS, Moloney WC, Hellman S. Total body irradiation as treatment for lymphosarcoma. Int J Radiat Oncol Biol Phys 1976; 1: 399-405.
33. Chaffey JT, Hellman S, Rosenthal DS, Moloney WC. Total-body irradiation in the treatment of lymphocytic lymphoma. Cancer Treat Rep 1977; 61: 1149-1152.
34. Brereton HD, Young RC, Longo DL, et al. A comparison between combination chemotherapy and total body irradiation plus combination chemotherapy in non-Hodgkin's lymphoma. Cancer 1979; 43: 2227-2231.
35. Carabell SC, Chaffey JT, Rosenthal DS, Moloney WC, Hellman S. Results of total body irradiation in the treatment of advanced non-Hodgkin's lymphomas. Cancer 1979; 43: 994-1000.
36. Leimert JT, Corder MP, Tewfik HH, Guthrie R, Maguire LC, Gingrich RD. Total body irradiation and cyclophosphamide, vincristine, prednisone in the treatment of favorable prognosis non-Hodgkin's lymphomas. Int J Radiat Oncol Biol Phys 1979; 5: 1479-1483.
37. Hoppe RT, Kushlan P, Kaplan HS, Rosenberg SA, Brown BW. The treatment of advanced stage favorable histology non-Hodgkin's lymphoma: a preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation. Blood 1981; 58: 592-598.
38. Dobbs HJ, Barrett A, Rostom AY, Peckham MJ. Total-body irradiation in advanced non-Hodgkin's lymphoma. Br J Radiol 1981; 54: 878-881.
39. Corder MP, Leimert JT, Tewfik HH, Lovett JM. Multimodality therapy of favorable prognosis non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 1983; 9: 1009-1012.
40. Jacobs P, King HS. A randomized prospective comparison of chemotherapy to total body irradiation as initial treatment for the indolent lymphoproliferative diseases. Blood 1987; 69: 1642-1646.
41. Mendenhall NP, Noyes WD, Million RR. Total body irradiation for stage II-IV non-Hodgkin's lymphoma: ten-year follow-up. J Clin Oncol 1989; 7: 67-74.
42. Lybeert ML, Meerwaldt JH, DeneveW. Long-term results of low dose total body irradiation for advanced non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 1987; 13: 1167-1172.
43. Meerwaldt JH, Carde P, Burgers JM, et al. Low-dose total body irradiation versus combination chemotherapy for lymphomas with follicular growth pattern. Int J Radiat Oncol Biol Phys 1991; 21: 1167-1172.
44. Roncadin M, Arcicasa M, Zagonel V, et al. Total body irradiation and prednimustine in chronic lymphocytic leukemia and low grade non-Hodgkin's lymphomas. A. 9-year experience at a single institution. Cancer 1994; 74: 978-984.
45. Haas RL, Poortmans P, de Jong D, et al. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol 2003; 21: 2474-2480.
46. Ganem G, Lambin P, Socie G, et al. Potential role for low dose limited-field radiation therapy (2×2 grays) in advanced low-grade non-Hodgkin's lymphomas. Hematol Oncol 1994; 12: 1-8.
47. Sawyer EJ, Timothy AR. Low dose palliative radiotherapy in low grade non-Hodgkin's lymphoma. Radiother Oncol 1997; 42: 49-51.
48. Johannsson J, Specht L, Mejer J, Jensen BA. Phase II study of palliative low-dose local radiotherapy in disseminated indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Int J Radiat Oncol Biol Phys 2002; 54: 1466-1470.
49. Haas RL, de Jong D, Valdes Olmos RA, et al. In vivo imaging of radiation induced apoptosis in follicular lymphoma patients. Int J Radiat Biol Oncol Phys. 2004; 59: 782-787.
50. Husson H, Carideo EG, Neuberg D, et al. Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays. Blood 2002; 99: 282-289.
51. Dubray B, Breton C, Delic J, et al. In vitro radiation-induced apoptosis and early response to low-dose radiotherapy in non-Hodgkin's lymphomas. Radiother Oncol 1998; 46: 185-191.
52. Dubray B, Breton C, Delic J, et al. In vitro radiation-induced apoptosis and tumour response to radiotherapy: a prospective study in patients with non-Hodgkin lymphomas treated by low-dose irradiation. Int J Radiat Biol 1997; 72: 759-760.
53. Verheij M, Bartelink H. Radiation-induced apoptosis. Cell Tissue Res 2000; 301: 133-142.
54. Blankenberg FG, Katsikis PD, Tait JF, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci USA 1998; 95: 6349-6354.
55. Blankenberg FG, Tait JF, Blankenberg TA, Post AM, Strauss HW. Imaging macrophages and the apoptosis of granulocytes in a rodent model of subacute and chronic abscesses with radiolabeled monocyte chemotactic peptide-1 and annexin V. Eur J Nucl Med 2001; 28: 1384-1393.
56. Blankenberg FG, Tait JF, Strauss HW. Apoptotic cell death: its implications for imaging in the next millennium. Eur J Nucl Med 2000; 27: 359-367.
57. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserineexpression on early apoptotic cells using fluorescein labeled Annexin V. J Immunol Methods 1995; 184: 39-51.
58. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 1994; 84: 1415-1420.
59. Blankenberg FG, Naumovski L, Tait JF, Post AM, Strauss HW. Imaging cyclophosphamide-induced intramedullary apoptosis in rats using 99 mTc-radiolabeled annexin V. J Nucl Med. 2001; 42: 309-316.
60. Ogura Y, Krams SM, Martinez OM, et al. Radiolabeled annexin V imaging: diagnosis of allograft rejection in an experimental rodent model of liver transplantation. Radiology. 2000; 214: 795-800.
61. Post AM, Katsikis PD, Tait JF, Geaghan SM, Strauss HW, Blankenberg FG. Imaging cell death with radiolabeled annexin V in an experimental model of rheumatoid arthritis. J Nucl Med 2002; 43: 1359-1365.
62. Kemerink GJ, Boersma HH, Thimister PW, Hofstra L, Liem IH, Pakbiers MT, et al. Biodistribution and dosimetry of 99 mTc-BTAP-annexin-V in humans. Eur J Nucl Med 2001; 28: 1373-1378.
63. Yang DJ, Azhdarinia A, Wu P, et al. In vivo and in vitro measurement of apoptosis in breast cancer cells using 99 mTc-EC-annexin V. Cancer Biother Radiopharm 2001; 16: 73-83.
64. Kemerink GJ, Liem IH, Hofstra L, et al. Patient dosimetry of intravenously administered 99 mTc-annexin V. J. Nucl Med 2001; 42: 382-387.
65. Ohtsuki K, Akashi K, Aoka Y, et al. Technetium-99m HYNICannexin V: a potential radiopharmaceutical for the in-vivo detection of apoptosis. Eur J Nucl Med 1999; 26: 1251-1258.
66. Blankenberg FG, Katsikis PD, Tait JF, et al. Imaging of apoptosis (programmed cell death) with 99 mTc annexin V. J Nucl Med 1999; 40: 184-191.
67. Belhocine T, Steinmetz N, Hustinx R, et al. Inreased uptake of the apoptosis-imaging agent (99 m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res 2002; 8: 2766-2774.
68. Knoops L, Haas RLM, de Kemp S, et al. In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma. Blood 2007; 110: 1116-1122.
69. Fei P, El Deiry WS. P53 and radiation responses. Oncogene 2003; 22: 5774-5783.
70. Ogilvy S, Metcalf D, Print CG, Bath ML, Harris AW, Adams JM. Constitutive Bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. Proc Natl Acad Sci USA 1999; 96: 14943-14948.
71. Langenau DM, Jette C, Berghmans S, et al. Suppression of apoptosis by bcl-2 overexpression in lymphoid cells of transgenic zebrafish. Blood 2005; 105: 3278-3285.
72. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98: 5116-5121.
73. Eldering E, Spek CA, Aberson HL, et al. Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways. Nucleic Acids Res 2003; 31: 153.
74. Haas RL, Poortmans Ph, de Jong D, Verheij M, van der Hulst M, de Boer JP, et al. Effective palliation by low dose local radiotherapy of 4Gy for recurrent and/or chemotherapy refractory non-follicula lymphoma patients. Eur J Cancer 2005; 41: 1724-1730.
75. WHO Classification of tumours. Pathology and Genetics, Tumours of the haematopoietic and lymphoid tissues, editors Jaffe, Harris, Stern and Vardiman. Oxford University Press: Lyon, France, 2001.